The reduction of hypoglycemia risk (66.9%) and dissatisfaction with prior therapies (55.8%) were also prominent factors, indicating that despite relatively preserved endogenous insulin production in T2DM, safety and convenience remain key drivers in treatment decisions. Here, INS is linked to Hypoglycemia.